FindTrial
Sign In

Study the role of FGFR/ FRS2a/PI3K/AKT in well-differentiated liposarcoma/dedifferentiated liposarcoma and its clinical application prospect

Study the role of FGFR/ FRS2a/PI3K/AKT in well-differentiated liposarcoma/dedifferentiated liposarcoma and its clinical application prospect

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100053479
Enrollment
Unknown
Registered
2021-11-22
Start date
2022-01-01
Completion date
Unknown
Last updated
2022-10-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Well differentiated liposarcoma/ dedifferentiated liposarcoma

Interventions

Liposarcoma group VS normal tissue group VS control group:Detection of the amplification of FRS2 gene and the expression of FGFR pathway molecules in liposarcoma, normal tissue and control tumor grou

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: The paraffin embedded tissue blocks which consist with well-differentiated liposarcoma/dedifferentiated liposarcoma histologically and those should be differ from liposarcoma(archived tissue).

Exclusion criteria

Exclusion criteria: No.

Design outcomes

Primary

MeasureTime frame
FRS2a gene amplification;FGFR/FRS2a/PI3K/Akt pathway activation;—

Countries

China

Contacts

Public ContactZhang Hongying

Pathology Department, West China Hospital, Sichuan University

hy_zhang@scu.edu.cn+86 18980601886

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026